



BIODIEM LTD
ABN 20 096 845 993
Level 10, South Tower,
459 Collins Street,
Melbourne, Victoria, 3000
Australia

Phone: +61 3 9613 4100
Web: www.biodiem.com
ASX: BDM

ASX Announcement

EXTENSION TO CLOSING DATE FOR RENOUNCEABLE RIGHTS ISSUE

New Closing Date - 16 November 2012

BioDiem Limited (ASX:BDM) announces an extension of the closing date for its current rights issue offer to shareholders.

On 28 September 2012, the Company announced a rights issue to shareholders to raise further working capital. The rights issue is a renounceable 1 for 2 offer of shares at an issue price of 5 cents, with every two shares subscribed for carrying a free-attaching option exercisable at 8 cents and expiring on 31 December 2014. The rights issue is seeking to raise up to AU\$2.55 million.

The Company is extending the closing date for the rights issue from Friday 2 November 2012 to Friday 16 November 2012. As a consequence, the date rights trading ends is now extended to 9 November 2012 (noting that this will allow for rights trading after a replacement prospectus is lodged as referred to below).

The new indicative timetable for the rights issue is below:

Event	Indicative Timing
Rights trading ends	9 November 2012
Closing Date	16 November 2012
Notice of Shortfall to ASX	22 November 2012
Despatch Date of Holding Statements	26 November 2012
Normal Trading Resumes	27 November 2012

Shareholders should note that the above timetable is subject to change depending upon the date of lodgement of a Replacement Prospectus by the Company as required by the Australian Securities and Investments Commission. If the above dates change, the Company will make a further announcement. The dates will also be set out in the replacement prospectus when lodged and distributed.

Further information

Investors

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9613 4100
Email jphillips@biodiem.com

Media

Tom Donovan
Buchan Consulting
Phone +61 3 8866 1224 / +61 422 557 107
Email tdonovan@buchanwe.com.au

About BioDiem Ltd

BioDiem is an ASX-listed company based in Melbourne with an international focus on discovering, developing and commercialising world-class research and technology targeting cancers and infectious diseases. BioDiem's core technologies include the Live Attenuated Influenza Virus (LAIV), the Savine platform and the BDM-I anti-microbial compound.

The LAIV influenza vaccine is an intranasal vaccine to prevent infection from seasonal and pandemic influenza. The LAIV influenza vaccine can be produced using both egg-based and cell-based manufacturing methods. The cell-based LAIV vaccine has completed a Phase II clinical trial in Europe. The egg-based LAIV vaccine technology is licensed to the World Health Organization as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

The LAIV influenza vaccine is marketed as Nasovac™ in India by the Serum Institute of India, and has been licensed to China-based Changchun BCHT Biotechnology Co. The LAIV vaccine was in-licensed from the Institute of Experimental Medicine in St Petersburg, Russia where it has been used for over a decade in many millions of people - children, adults and the elderly. The LAIV is administered by nasal spray and induces a rapid immune response in the mucosal lining of the nose and pharynx.

The LAIV is also being developed as a viral vector for making novel non-influenza vaccines for different diseases including cancers. Viruses have the ability to generate proteins prolifically and can be programmed to produce disease-specific proteins. As part of a vaccine, disease-specific proteins can help generate a beneficial immune response.

SAVINE (patented Scrambled Antigen Vaccine) is a platform technology for the design of antigens for incorporation into vaccines targeting an immune response to a range of different diseases. SAVINE antigens are encoded as synthetic genes which, together with a delivery technology such as BioDiem's LAIV-based vaccine vector technology, can be used to develop novel vaccines.

BioDiem is also developing BDM-E, a tetra peptide synthetic compound, as a treatment for ophthalmic disorders. The US Food & Drug Administration (USFDA) has granted Orphan Drug designation to BDM-E for the treatment of retinitis pigmentosa, a serious degenerative disease of the retina.

BioDiem's research is ongoing in partnerships with internationally recognised laboratories.

For additional information, please visit www.biodiem.com